Contact Us
  • Choose License Type

Global Viscosupplementation Market, by Treatment (Single Injection Treatment Cycle, Three Injection Treatment Cycle, and Five Injection Treatment Cycle) by Application (Knee Osteoarthritis, Hip Osteoarthritis, and Others) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be valued at US$ 2,524.8 Mn in 2019 and is expected to surpass US$ 4,738.8 Mn by 2027, witnessing a CAGR of 8.2% over the forecast period (2019-2027) as highlighted in a new report published by Coherent Market Insights.

Manufacturers are engaged in developing new viscosupplementation products to improve osteoarthritis treatment, which, in turn, has led to an increase in product launches and approvals. These factors are expected to boost the global viscosupplementation market growth. For instance, in December 2019, Fidia Pharma USA Inc., a wholly-owned subsidiary of Fidia Pharmaceutics S.P.A., launched TRILURON (sodium hyaluronate) in the U.S. and also received the U.S. Food and Drug Administration’s (FDA) Pre-Market Approval in April 2019. The TRILURON treatment cycle consists of three injections given at weekly intervals.

Moreover, in 2015, Bioventus, a global leader in orthobiologic solutions, launched SUPARTZ FX, a five–injection, hyaluronic acid (HA) product for the treatment of knee osteoarthritis pain. Furthermore, in 2015, OrthogenRx Inc. received the U.S. Food and Drug Administration’s (FDA) approval for its product GenVisc 850 (sodium hyaluronate). GenVisc 850 is used for the treatment of patients suffering from knee pain associated with osteoarthritis (OA).

Several organizations, and institutions are engaged in raising awareness regarding osteoarthritis, and providing information regarding its symptoms and prevention. This is also expected to positively impact growth of the global viscosupplementation market. For instance, in April 2019, the International Association for Study of Pain initiated ‘Real Women, Real Pain’ awareness campaign for pain and pain-related issues affecting women across the world. Furthermore, in May, Osteoarthritis Action Alliance (OAAA) launched ‘StandUP2OA’, a new comprehensive campaign focused on spreading awareness about osteoarthritis and its prevention.

Browse 24 Market Data Tables, and 26 Figures spread through 160 Pages and in-depth TOC on Global Viscosupplementation Market, by Treatment (Single Injection Treatment Cycle, Three Injection Treatment Cycle, Five Injection Treatment Cycle) by Application (Knee Osteoarthritis, Hip Osteoarthritis and others) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Global Forecast to 2027

To know the latest trends and insights prevalent in the viscosupplementation market, click the link below:

https://www.coherentmarketinsights.com/market-insight/viscosupplementation-market-197

Manufacturers are focused on strengthening their distribution network by signing distributive agreements in order to increase the supply of their products all over the world. This, in turn, is expected to propel the global viscosupplementation market growth.  For instance, in February 2018, Bioventus extended its distribution agreement with Seikagaku Corporation to distribute its product, SUPARTZ FX, a five-injection hyaluronic acid (HA) product, in the U.S. Moreover, in October 2017, Mylan N.V. and Unimedic Group entered into an exclusive distribution agreement spanning over 5 years, for distribution of its product ‘Suplasyn’ in all Nordic countries.

Key takeaways of the global viscosupplementation market:

  • The global viscosupplementation market is expected to exhibit a CAGR of 8.2% over the forecast period (2019-2027), owing to frequent product approvals and launches, as well as adoption of inorganic growth strategies such as collaborations and partnerships among key players.
  • On the basis of treatment, the three injection treatment cycle segment is expected to hold a dominant position in the global viscosupplementation market over the forecast period, owing to product availability, and increasing product approvals and launches of three injection treatment cycle viscosupplementation products.
  • For instance, all the major players including Anika Therapeutics Inc., Seikagaku Corporation, Ferring Pharmaceuticals, Bioventus, Fidia Farmaceutici S.P.A, and others offers three injection treatment cycle products.
  • Based on application, the knee osteoarthritis segment is expected to witness significant growth owing to increasing incidence of most common orthopedic disorder such as knee and hip osteoarthritis.
  • Some of the major players involved in the global viscosupplementation market are Anika Therapeutics Inc., Seikagaku Corporation, Ferring Pharmaceuticals, Bioventus, Fidia Farmaceutici S.P.A., Mylan N.V., Sanofi S.A., OrthogenRx, Teva Pharmaceutical Industries Ltd, and Johnson & Johnson.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner